What MC10 does

MC10 Inc. is a Lexington, Massachusetts-based company founded in 2008 as a University of Illinois spinout commercializing stretchable, conformal electronic sensor technology originally developed by Professor John Rogers. The company built thin, flexible 'electronic skin' (e-skin) sensor platforms capable of capturing continuous physiological data — including ECG-like signals, motion, and vital signs — from body-conformable devices. This sensor output was processed through proprietary algorithms into clinical-grade digital biomarkers intended for remote patient monitoring, clinical trial endpoints, and AI-enhanced diagnostic applications.

MC10 operated as a B2B technology licensor and co-development partner rather than a branded consumer product company. Its target customers included pharmaceutical companies and contract research organizations (for digital biomarker-based clinical trial endpoints), medical device and wearable technology companies (for sensor platform integration), and healthcare providers seeking AI-enhanced diagnostic and monitoring capabilities. Revenue was generated through technology licensing, sensor and algorithm sales to enterprise healthcare customers, and OEM co-development agreements — exemplified by the 2013 Motorola partnership on a 'temporary password tattoo' biometric authentication concept. The company was repeatedly cited in market research as a key player in the electronic skin and North America AI Diagnostics markets alongside Samsung, Philips Healthcare, Medtronic, and Siemens Healthineers.

By 2025-2026, Medidata (a Dassault Systèmes company) had acquired MC10's digital biomarker business, integrating its sensor technology and validated algorithms into Medidata's Sensor Cloud platform for regulated clinical trials. The full operating status of MC10 as an independent entity following this divestiture is unclear. Across its lifetime, MC10 raised approximately $97M in disclosed equity funding across 13 rounds between 2010 and 2018 from investors including Medtronic, Aberdare Ventures, Braemar Energy Ventures, North Bridge Venture Partners, and Haiyin Capital.

Name

MC10

Legal name

MC10 Inc.

Website

https://mc10inc.com

Company type

Private

Founded year

2008

Operating status

Acquired

Headcount range

11–50 employees

Short description

MC10 Inc. is a Lexington, Massachusetts-based company founded in 2008 that developed stretchable, conformal electronic sensor ('e-skin') technology for capturing continuous physiological data and converting it into clinical-grade digital biomarkers. The company served pharmaceutical firms, CROs, medical device companies, and healthcare providers through technology licensing and co-development partnerships.

Ownership category

akta.pro rank

Product category

Wearable Medical Sensors

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Stretchable electronics
• Digital biomarkers
• Wearable sensors
• Biometric monitoring
• Electronic skin

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Digital Biomarker Licensing and Technology Licensing: MC10 generated revenue by licensing its digital biomarker technology, sensor platforms, and associated algorithms to healthcare, medical device, and clinical research companies. The acquisition of its digital biomarker business by Medidata (a Dassault Systèmes company) indicates MC10's revenue included technology licensing and/or IP commercialization. The company sold or licensed its sensor technology for integration into third-party healthcare platforms and diagnostic products.
2. B2B Sensor and Algorithm Sales to Enterprise Customers: MC10 sold sensor technology, platforms, and data processing solutions directly to enterprise healthcare customers (pharma, medtech, CROs) as a B2B supplier. Evidence of engagement with Medidata and presence in the clinical trials ecosystem suggests revenue from selling sensor-based digital measures to pharmaceutical companies and clinical research organizations for use in drug development and clinical trials.
3. Co-development and OEM Partnerships: MC10 engaged in co-development projects with partners such as Motorola (on biometric authentication tattoos) and presumably other healthcare/technology companies. This revenue stream involved collaborative development agreements, potentially including upfront payments, milestone payments, and/or ongoing royalties from co-developed products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

MC10 develops virtually invisible, conformal flexible electronics and stretchable biometric sensor platforms that capture continuous physiological data (ECG, motion, vital signs) from skin-worn devices. The company converts these sensor signals into clinical-grade digital biomarkers and validated algorithms for remote patient monitoring, clinical trials, diagnostic decision support, and biometric authentication applications.

Differentiator

Problem solved

Functional benefit

Products and services

• MC10 Stretchable Biometric Sensor Platform
• MC10 Digital Biomarker Solutions

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Medidata (Dassault Systèmes)coreTechnology or Integration · 1 January 2025Medidata, a Dassault Systèmes company and leading provider of clinical trial technology, acquired MC10's digital biomarker business in 2025-2026 as a notable industry development. The acquisition integrated MC10's sensor technology and validated algorithms into Medidata's Sensor Cloud platform, enabling continuous medical-grade data capture and digital endpoint generation for regulated clinical trials. This acquisition represents the most significant documented commercial relationship involving MC10 and validates the strategic value of MC10's digital biomarker technology.
• Motorola Mobility (Google)minorStrategic or Co-development PartnerMC10 partnered with Motorola Mobility (owned by Google at the time) to develop a 'temporary password tattoo' — a stretchable biometric patch that generated an 18-bit ECG-like authentication signal for body-as-authentication-token applications. The concept was demonstrated at the All Things Digital D11 conference in California in 2013, developed under the direction of former DARPA chief Regina Dugan and in partnership with Proteus Digital Health (which had prior FDA clearance for ingestible sensors). The concept was demonstrated working but never reached commercial shipment. This partnership demonstrated MC10's stretchable biometric sensor capabilities in a novel authentication use case.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Medtronic: Medtronic is both a strategic investor in MC10 and a listed peer in the North America AI Diagnostics Market. It operates broadly across implanted and wearable cardiac/diagnostic devices, overlapping with MC10's conformal sensor and digital biomarker roadmap.
• Philips Healthcare: Philips Healthcare was listed alongside MC10 as a key player in the global electronic skin market and is a major incumbent in patient monitoring, biosensors, and connected health — competing with MC10 across multiple overlapping categories from a vastly larger base.
• Siemens Healthineers: Siemens Healthineers was named alongside MC10 as a key player in the North America AI Diagnostics Market. It provides a broad portfolio of diagnostic imaging, AI-enabled clinical decision support, and patient monitoring — an incumbent footprint that overlaps with MC10's diagnostic ambitions.

Direct peers

• VivaLNK: VivaLNK provides continuous wearable vital signs sensors and a connected health platform used in remote patient monitoring and clinical trials. It overlaps directly with MC10's clinical-grade wearable sensor and digital biomarker offering for pharma and CRO customers.
• iRhythm Technologies: iRhythm's Zio wearable cardiac monitor captures continuous ECG data and converts it into clinical-grade digital measures via AI — competing with MC10's conformal ECG/motion capture capabilities in the digital biomarker and remote cardiac monitoring space.
• Empatica: Empatica builds FDA-cleared wearable sensors and digital biomarkers (e.g., EpiMonitor for epilepsy) that continuously capture physiological signals for clinical research and remote monitoring — directly competing with MC10's stretchable e-skin approach to digital biomarker generation.
• Proteus Digital Health: Proteus developed ingestible and wearable digital medicines that capture physiological adherence and response data. MC10 partnered with Proteus on the Motorola biometric tattoo demonstration, and both companies share the digital biomarker / body-conformal sensor thesis for clinical trials.
• Oxitone Medical: Oxitone develops continuous, wrist-worn vital signs monitoring devices with AI-driven analytics for clinical and remote patient monitoring. It was named alongside MC10 as a key player in the North America AI Diagnostics Market and operates in the same connected wearable diagnostics category.

Emerging players

• BioIntellisense: BioIntellisense offers the BioSticker and BioButton continuous wearable vital signs monitoring devices for remote patient monitoring and clinical research — an emerging player in the same clinical-grade wearable biomarker category as MC10.
• Xsensio: Xsensio is developing a lab-on-chip skin-worn wearable platform for continuous biochemical and physiological monitoring — an emerging player in the ultra-miniaturized, skin-conformal biosensor category that overlaps with MC10's stretchable e-skin thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/mc10inc
• LinkedInlinkedin.com/company/mc10

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds12 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MC10